Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain

References

• National Genomics Data Center, China National Center for Bioinformation / Beijing Institute of Genomics, Chinese Academy of Sciences. Released Genome Sequences. 2021.
   Google Scholar
• WHO. Tracking SARS-CoV-2 variants. WHO. 2021. https://wwwwhoint/en/activities/tracking-SARS-CoV-2-variants/ .
   Google Scholar
• WHO. Weekly epidemiological update on COVID-19 - 21 December 2021. WHO. 2021. https://wwwwhoint/publications/m/item/weekly-epidemiological-update-on-covid-19—21-december-2021 .
   Google Scholar
• WHO. Weekly epidemiological update on COVID-19 - 1 March 2022. 2022. WHO. https://wwwwhoint/publications/m/item/weekly-epidemiological-update-on-covid-19—1-march-2022 .
   Google Scholar
• Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281–92.e286. doi:10.1016/j.cell.2020.02.058.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–80.e278. doi:10.1016/j.cell.2020.02.052.
   PubMed Web of Science ®Google Scholar
• Papageorgiou AC, Mohsin I. The SARS-CoV-2 Spike Glycoprotein as a drug and vaccine target: structural insights into its complexes with ACE2 and antibodies. Cells. 2020;9(11). doi:10.3390/cells9112343.
   Web of Science ®Google Scholar
• Barnes CO, West AP Jr., Huey-Tubman KE, Hoffmann MAG, Sharaf NG, Hoffman PR, Koranda N, Gristick HB, Gaebler C, Muecksch F, et al. Structures of human antibodies bound to SARS-CoV-2 Spike reveal common epitopes and recurrent features of antibodies. Cell. 2020;182(4):828–42.e816. doi:10.1016/j.cell.2020.06.025.
   PubMed Web of Science ®Google Scholar
• Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L, Zhu Q, Zhang X, Zheng Y, Geng C, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell. 2020;182(1):73–84.e16. doi:10.1016/j.cell.2020.05.025.
   PubMed Web of Science ®Google Scholar
• Du S, Cao Y, Zhu Q, Yu P, Qi F, Wang G, Du X, Bao L, Deng W, Zhu H, et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. 2020;183(4):1013–23.e13. doi:10.1016/j.cell.2020.09.035.
   PubMed Web of Science ®Google Scholar
• Piccoli L, Park YJ, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, Silacci-Fregni C, Pinto D, Rosen LE, Bowen JE, et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 Spike receptor-binding domain by structure-guided high-resolution serology. Cell. 2020;183(4):1024–42.e21. doi:10.1016/j.cell.2020.09.037.
   PubMed Web of Science ®Google Scholar
• Shi R, Shan C, Duan X, Chen Z, Liu P, Song J, Song T, Bi X, Han C, Wu L, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020;584(7819):120–11. doi:10.1038/s41586-020-2381-y.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, Luo Y, Chan JF, Sahi V, Figueroa A, et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020;584(7821):450–56. doi:10.1038/s41586-020-2571-7.
   PubMed Web of Science ®Google Scholar
• Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, Zhang Z, Fan P, Dong Y, Yang Y, et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020;369(6504):650–55. doi:10.1126/science.abc6952.
   PubMed Web of Science ®Google Scholar
• Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, Giordano S, Lanza K, Negron N, Ni M, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369(6506):1014–18. doi:10.1126/science.abd0831.
   PubMed Web of Science ®Google Scholar
• Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, Cornaby C, Bartelt L, Weiss S, Park Y, et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020;5(48). doi:10.1126/sciimmunol.abc8413.
   PubMed Web of Science ®Google Scholar
• Anderson EM, Goodwin EC, Verma A, Arevalo CP, Bolton MJ, Weirick ME, Gouma S, McAllister CM, Christensen SR, Weaver J, et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. Cell. 2021;184(7):1858–64.e1810. doi:10.1016/j.cell.2021.02.010.
   PubMed Web of Science ®Google Scholar
• Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, Ulferts R, Earl C, Wrobel AG, Benton DJ, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020;370(6522):1339–43. doi:10.1126/science.abe1107.
   PubMed Web of Science ®Google Scholar
• Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Rawlings SA, Sutherland A, Premkumar L, Jadi RS, et al. Targets of T cell responses to SARS-CoV-2 Coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489–501.e1415. doi:10.1016/j.cell.2020.05.015.
   PubMed Web of Science ®Google Scholar
• Ladner JT, Henson SN, Boyle AS, Engelbrektson AL, Fink ZW, Rahee F, D’-Ambrozio J, Schaecher KE, Stone M, Dong W, et al. Epitope-Resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses. Cell Rep Med. 2021;2(1):100189. doi:10.1016/j.xcrm.2020.100189.
   PubMedGoogle Scholar
• Zhang L, Cao L, Gao XS, Zheng BY, Deng YQ, Li JX, Feng R, Bian Q, Guo XL, Wang N, et al. A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2. Natl Sci Rev. 2021;8(8):nwab053. doi:10.1093/nsr/nwab053.
   PubMed Web of Science ®Google Scholar
• Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, Nutalai R, Zhou D, Mentzer AJ, Zhao Y, et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021;184(16): 4220–4236.e13. doi:10.1016/j.cell.2021.06.020.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhou T, Zhang Y, Yang ES, Schramm CA, Shi W, Pegu A, Oloniniyi OK, Henry AR, Darko S, et al. Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science. 2021;373(6556):6556. doi:10.1126/science.abh1766.
   Web of Science ®Google Scholar
• Barbas CF 3rd, Kang AS, Lerner RA, Benkovic SJ. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci U S a. 1991;88(18):7978–82. doi:10.1073/pnas.88.18.7978.
   PubMed Web of Science ®Google Scholar
• Chen Z, Ren X, Yang J, Dong J, Xue Y, Sun L, Zhu Y, Jin Q. An elaborate landscape of the human antibody repertoire against enterovirus 71 infection is revealed by phage display screening and deep sequencing. mAbs. 2017;9(2):342–49. doi:10.1080/19420862.2016.1267086.
   PubMed Web of Science ®Google Scholar
• Somasundaram R, Choraria A, Antonysamy M. An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: a review. Int Immunopharmacol. 2020;85:106654. doi:10.1016/j.intimp.2020.106654.
   PubMed Web of Science ®Google Scholar
• Andreano E, Nicastri E, Paciello I, Pileri P, Manganaro N, Piccini G, Manenti A, Pantano E, Kabanova A, Troisi M, et al. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. Cell. 2021;184(7):1821–35.e1816. doi:10.1016/j.cell.2021.02.035.
   PubMed Web of Science ®Google Scholar
• Zheng Z, Monteil VM, Maurer-Stroh S, Yew CW, Leong C, Mohd-Ismail NK, Cheyyatraivendran Arularasu S, Chow VTK, Lin RTP, Mirazimi A, et al. Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2. Euro Surveill. 2020;25(28). doi:10.2807/1560-7917.ES.2020.25.28.2000291.
   Google Scholar
• Nguyen-Contant P, Embong AK, Kanagaiah P, Chaves FA, Yang H, Branche AR, Topham DJ, Sangster MY, Ellebedy A, Schultz-Cherry S. S protein-reactive IgG and memory B cell production after human SARS-CoV-2 infection includes broad reactivity to the S2 subunit. mBio. 2020;11(5). doi:10.1128/mBio.01991-20.
   PubMed Web of Science ®Google Scholar
• Poh WP, Narasaraju T, Pereira NA, Zhong F, Phoon MC, Macary PA, Wong SH, Lu J, Koh DR, Chow VT. Characterization of cytotoxic T-lymphocyte epitopes and immune responses to SARS coronavirus spike DNA vaccine expressing the RGD-integrin-binding motif. J Med Virol. 2009;81(7):1131–39. doi:10.1002/jmv.21571.
   PubMed Web of Science ®Google Scholar
• Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, Hippenstiel S, Dingeldey M, Kruse B, Fauchere F, et al. SARS-CoV-2-Reactive T cells in healthy donors and patients with COVID-19. Nature. 2020;587(7833):270–74. doi:10.1038/s41586-020-2598-9.
   PubMed Web of Science ®Google Scholar
• Meckiff BJ, Ramírez-Suástegui C, Fajardo V, Chee SJ, Kusnadi A, Simon H, Eschweiler S, Grifoni A, Pelosi E, Weiskopf D, et al. Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4(+) T Cells in COVID-19. Cell. 2020;183(5):1340–53.e1316. doi:10.1016/j.cell.2020.10.001.
   PubMed Web of Science ®Google Scholar
• Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, Chng MHY, Lin M, Tan N, Linster M, et al. SARS-CoV-2-Specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584(7821):457–62. doi:10.1038/s41586-020-2550-z.
   PubMed Web of Science ®Google Scholar
• Weiskopf D, Schmitz KS, Raadsen MP, Grifoni A, Okba NMA, Endeman H, van den Akker JPC, Molenkamp R, Koopmans MPG, van Gorp ECM, et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci Immunol. 2020;5(48). doi:10.1126/sciimmunol.abd2071.
   Web of Science ®Google Scholar
• Zheng J. SARS-CoV-2: an emerging Coronavirus that causes a global threat. Int J Biol Sci. 2020;16(10):1678–85. doi:10.7150/ijbs.45053.
   PubMed Web of Science ®Google Scholar
• Du P, Gao GF, Wang Q. The mysterious origins of the Omicron variant of SARS-CoV-2. Innovation (New York, NY). 2022;3:100206. doi:10.1016/j.xinn.2022.100206.
   PubMedGoogle Scholar
• Martin DP, Lytras S, Lucaci AG, Maier W, Grüning B, Shank SD, Weaver S, MacLean OA, Orton RJ, Lemey P, et al. Selection analysis identifies unusual clustered mutational changes in Omicron lineage BA.1 that likely impact Spike function. Mol Biol Evol. 2022. doi:10.1093/molbev/msac061.
   Google Scholar
• Peacock TP, Brown JC, Zhou J, Thakur N, Newman J, Kugathasan R, Sukhova K, Kaforou M, Bailey D, Barclay WS. The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry. 2022. bioRxiv. doi:10.1101/2021.12.31.474653.
   Google Scholar
• Bate N, Savva CG, Moody PC, Brown EA, Ball JK, Schwabe JW, Sale JE, Brindle NP. In vitro evolution predicts emerging CoV-2 mutations with high affinity for ACE2 and cross-species binding. 2021.2012.2023.473975. 2021.
   Google Scholar
• Dejnirattisai W, Huo J, Zhou D, Zahradník J, Supasa P, Liu C, Duyvesteyn HME, Ginn HM, Mentzer AJ, Tuekprakhon A, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022;185(3):467–84.e415. doi:10.1016/j.cell.2021.12.046.
   PubMed Web of Science ®Google Scholar
• Garcia-Beltran WF, St Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, Berrios C, Ofoman O, Chang CC, Hauser BM, et al. mRNA-Based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2022;185(3):457–66.e454. doi:10.1016/j.cell.2021.12.033.
   PubMed Web of Science ®Google Scholar
• Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, Bolland WH, Porrot F, Staropoli I, Lemoine F, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602(7898):671–75. doi:10.1038/s41586-021-04389-z.
   PubMed Web of Science ®Google Scholar
• Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, Huang W, Li Q, Wang P, An R, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602(7898):657–63. doi:10.1038/s41586-021-04385-3.
   PubMed Web of Science ®Google Scholar
• Jennewein MF, MacCamy AJ, Akins NR, Feng J, Homad LJ, Hurlburt NK, Seydoux E, Wan YH, Stuart AB, Edara VV, et al. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. Cell Rep. 2021;36(2):109353. doi:10.1016/j.celrep.2021.109353.
   PubMed Web of Science ®Google Scholar
• Wang C, van Haperen R, Gutiérrez-Álvarez J, Li W, Okba NMA, Albulescu I, Widjaja I, van Dieren B, Fernandez-Delgado R, Sola I, et al. A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies. Nat Commun. 2021;12(1):1715. doi:10.1038/s41467-021-21968-w.
   PubMed Web of Science ®Google Scholar
• Chen EC, Gilchuk P, Zost SJ, Suryadevara N, Winkler ES, Cabel CR, Binshtein E, Chen RE, Sutton RE, Rodriguez J, et al. Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals. Cell Rep. 2021;36(8):109604. doi:10.1016/j.celrep.2021.109604.
   PubMed Web of Science ®Google Scholar
• Huang KA, Tan TK, Chen TH, Huang CG, Harvey R, Hussain S, Chen CP, Harding A, Gilbert-Jaramillo J, Liu X, et al. Breadth and function of antibody response to acute SARS-CoV-2 infection in humans. PLoS Pathog. 2021;17(2):e1009352. doi:10.1371/journal.ppat.1009352.
   PubMed Web of Science ®Google Scholar
• Shiakolas AR, Kramer KJ, Wrapp D, Richardson SI, Schäfer A, Wall S, Wang N, Janowska K, Pilewski KA, Venkat R, et al. Cross-Reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Rep Med. 2021;2(6):100313. doi:10.1016/j.xcrm.2021.100313.
   PubMedGoogle Scholar
• Amanat F, Thapa M, Lei T, Ahmed SMS, Adelsberg DC, Carreño JM, Strohmeier S, Schmitz AJ, Zafar S, Zhou JQ, et al. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell. 2021;184(15):3936–48.e3910. doi:10.1016/j.cell.2021.06.005.
   PubMed Web of Science ®Google Scholar
• Liao B, Chen Z, Zheng P, Li L, Zhuo J, Li F, Li S, Chen D, Wen C, Cai W, et al. Detection of anti-SARS-CoV-2-S2 IgG is more sensitive than anti-RBD IgG in identifying asymptomatic COVID-19 patients. Front Immunol. 2021;12:724763. doi:10.3389/fimmu.2021.724763.
   PubMed Web of Science ®Google Scholar
• Ma ML, Shi DW, Li Y, Hong W, Lai DY, Xue JB, Jiang HW, Zhang HN, Qi H, Meng QF, et al. Systematic profiling of SARS-CoV-2-specific IgG responses elicited by an inactivated virus vaccine identifies peptides and proteins for predicting vaccination efficacy. Cell Discovery. 2021;7(1):67. doi:10.1038/s41421-021-00309-7.
   PubMed Web of Science ®Google Scholar
• Dawood RM, El-Meguid MA, Salum GM, El-Wakeel K, Shemis M, El Awady MK. Bioinformatics prediction of B and T cell epitopes within the spike and nucleocapsid proteins of SARS-CoV2. J Infect Public Health. 2021;14(2):169–78. doi:10.1016/j.jiph.2020.12.006.
   PubMed Web of Science ®Google Scholar
• Gillot C, Douxfils J, Cadrobbi J, Laffineur K, Dogné JM, Elsen M, Eucher C, Melchionda S, Modaffarri É, Tré-Hardy M, et al. An original ELISA-based multiplex method for the simultaneous detection of 5 SARS-CoV-2 IgG antibodies directed against different antigens. J Clin Med. 2020;9(11):3752. doi:10.3390/jcm9113752.
   PubMed Web of Science ®Google Scholar
• Demers-Mathieu V, DaPra C, Mathijssen G, Sela DA, Jarvinen KM, Seppo A, Fels S, Medo E. Human milk antibodies against S1 and S2 subunits from SARS-CoV-2, HCoV-OC43, and HCoV-229E in Mothers with a confirmed COVID-19 PCR, viral SYMPTOMS, and unexposed mothers. Int J Mol Sci. 2021;22(4):1749. doi:10.3390/ijms22041749.
   PubMed Web of Science ®Google Scholar